Status:
COMPLETED
Oral Androgens in Man-3 (ORAL T-3) Pharmacokinetics of Oral Testosterone
Lead Sponsor:
University of Washington
Collaborating Sponsors:
GlaxoSmithKline
National Institutes of Health (NIH)
Conditions:
Contraception
Hypogonadism
Eligibility:
MALE
18-50 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to test the how the body absorbs and processes new forms of oral testosterone. Information gained during the study may help develop better forms of testosterone therapy in...
Detailed Description
The drug Lupron, will temporarily turn off the body's production of testosterone after two weeks. At that point, we will administer testosterone by mouth on six days in the next two weeks to see how m...
Eligibility Criteria
Inclusion
- Male 18-50 yrs old
- In good general health based on normal screening evaluation (consisting of medical history, physical exam, normal serum chemistry, hematology, and baseline hormone levels)
Exclusion
- Poor general health, with abnormal blood results at screening
- A known history of alcohol or drug abuse
- Participation in a long-term male contraceptive study within three months of screening
Key Trial Info
Start Date :
March 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2006
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT00161421
Start Date
March 1 2005
End Date
July 1 2006
Last Update
September 19 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Washington
Seattle, Washington, United States, 98195